SEARCH

SEARCH BY CITATION

References

  • 1
    Pawankar R, Yamagishi S, Yagi T. Revisiting the roles of mast cells in allergic rhinitis and its relation to local IgE synthesis. Am J Rhinol 2000;14: 309317.
  • 2
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108: S147S334.
  • 3
    Van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55: 116134.
  • 4
    Ciprandi G, Vizzaccaro A, Cirillo I, Crimi P, Canonica G. Increase of asthma and allergic rhinitis prevalence in young Italian men. Int Arch Allergy Immunol 1996;111: 279283.
  • 5
    Strachan D, Sibbald B, Weiland S et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8(Suppl. 5):161176.
  • 6
    Anthes JC, Richard C, West RE et al. Functional characteristics of descarboxyloratadine and other antihistamines in human histamine H1-receptors. J Allergy Clin Immunol 2000;104: S385.
  • 7
    Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107: 751762.
  • 8
    Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997;27: 559567.
  • 9
    Lippert U. Binding and antiallergic characteristics of desloratadine. Abstract 325. Allergy 2001;56(Suppl. 68):112.
  • 10
    Lebel B, Bousquet J, Czarlewski W et al. Loratadine (L) reduces RANTES release by an epithelial cell line. J Allergy Clin Immunol 1997;99: S44.
  • 11
    Lippert U, Kruger-Krasagakes S, Moller A, Kiessling U, Czarnetzki BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist descarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995;4: 272276.
  • 12
    Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001;31: 13691377.
  • 13
    Vignola AM, Crampette L, Mondain M et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995;50: 200203.
  • 14
    Bachert C, De Schryver L, Holtappels G. Effects of desloratadine (DL) on human monocyte activity in-vitro. Allergy 2002;57(Suppl. 73):145.
  • 15
    Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997;27: 11671174.
  • 16
    Straff B, Sachs B, Erdmann S, Merk HF. Wasp venom-induced IL-5, IL-10, and IFN-γ secretion from human PBMC from patients with wasp venom allergy is diversely inhibited by loratadine, desloratadine and cimetidine. Allergy 2002;57(Suppl. 73):155.
  • 17
    Wittmann M, Stunkel T, Kapp A, Werfel T. Immunoregulatory influence of descarboxyloratadine (DCL) on human lymphocytes. Allergy 2002;57(Suppl. 73):147.
  • 18
    Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56(Suppl. 56):1420.
  • 19
    Biller H, Kunze S, Luttman W, Virchow JC. Effects of desloratadine (DL) on Th2-cytokine secretion of peripheral blood leukocytes from patients with allergic rhinitis, patients with allergic asthma, and healthy controls. Allergy 2002;57(Suppl. 73):146.
  • 20
    Agrawal DK, Berro A, Townley RG. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation. Allergy 2000;55(Suppl. 63):276.
  • 21
    Huger M, Traidl-Hoffmann C, Kasche A, Ring J, Behrendt H. Influence of desloratadine on the chemotactic activity of human polymorphonuclear leukocytes. Allergy 2002;57(Suppl. 73):38.
  • 22
    Marshall G, Henninger E, Maniatis E, Ritter S, Salicru A, Messick C. Immunomodulatory effects of desloratadine: changes in type-1/type-2 cytokine expression in PBMC cultures. J Allergy Clin Immunol 2002;109(Suppl.):S206S207.
  • 23
    Cyr MM, Baatjes AJ, Hayes LM, Crawford L, Denburg JA. The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. Abstract 329. J Allergy Clin Immunol 2002;109: S117.
  • 24
    Dubuske L. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks. J Allergy Clin Immunol 2001;107: S159.
  • 25
    Meltzer EO, Prenner BM, Nayak A et al. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis assessment during the spring and fall allergy season. Clin Drug Invest 2001;21: 2532.
  • 26
    Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40: 7276.
  • 27
    Ratner PH, Group DS. Desloratadine improved asthma symptoms and reduce bronchodilator use in 2 studies of patients with asthma and SAR. Allergy Asthma Immunol 2000;86: 109.
  • 28
    Wilken JA, Kane RL. The differential impacts of diphenhydramine and desloratadine on vigilance and cognitive functioning in subjects with ragweed induced allergic rhinitis. Allergy 2002;57(Suppl. 73):236.
  • 29
    Plenker A, Bachert C. Treatment of seasonal allergic rhinitis with desloratadine: results of a large German observational study. Allergy 2002;57(Suppl. 73):4748.
  • 30
    Data on file. Schering-Plough, 2002.
  • 31
    Bachert C, Virchow CJ, Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study. Clin Drug Invest 2002;22(Suppl. 2):4352.